0001104659-24-043092.txt : 20240403 0001104659-24-043092.hdr.sgml : 20240403 20240403160513 ACCESSION NUMBER: 0001104659-24-043092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morabito Christopher CENTRAL INDEX KEY: 0001859284 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37467 FILM NUMBER: 24818668 MAIL ADDRESS: STREET 1: C/O FULCRUM THERAPEUTICS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Astria Therapeutics, Inc. CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 1400 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 1400 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: CATABASIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090127 4 1 tm2410392-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-04-01 0 0001454789 Astria Therapeutics, Inc. ATXS 0001859284 Morabito Christopher C/O ASTRIA THERAPEUTICS, INC. 75 STATE STREET, SUITE 1400 BOSTON MA 02109 0 1 0 0 Chief Medical Officer 1 Common Stock 2024-04-01 4 M 0 10000 3.87 A 10000 D Common Stock 2024-04-01 4 S 0 10000 13.5939 D 0 D Stock Option (Right to Buy) 3.87 2024-04-01 4 M 0 10000 0 D 2032-07-31 Common Stock 10000 80000 D This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.76, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. This option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. /s/ Ben Harshbarger, as attorney-in-fact for Christopher Morabito 2024-04-03